ABSTRACT Background: There is evidence that renal transplant recipients have accelerated atherosclerosis that is manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress, and inflammation associated with immunosuppressive therapy. The carotenoid astaxanthin has shown potent antioxidant and anti-inflammatory properties. Objective: The aim was to investigate the effects of oral astaxanthin on arterial stiffness, oxidative stress, and inflammation in renal transplant recipients. Design: This trial used a randomized, placebo-controlled, doubleblind design in which 61 patients received either 12 mg astaxanthin/ d or an identical placebo orally for 1 y. Primary outcomes were 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2) oxidative stress assessed by total plasma F2-isoprostanes, and 3) inflammation assessed by plasma pentraxin-3. Secondary outcomes included vascular function, carotid artery intima-media thickness, augmentation index, central blood pressure, subendocardial viability ratio, and additional measures of oxidative stress and inflammation. Patients underwent assessments at baseline and at 6 and 12 mo. Results: Fifty-eight participants completed the study. There were no significant between-group differences in the changes in any of the primary outcome measures (PWV changed by +9.5% and +6.0%, F2-isoprostanes changed by 23.0% and 29.7%, and pentraxin-3 changed by +50.6% and 211.0% in the placebo and astaxanthin groups, respectively). There were no significant between-group differences in secondary outcome measures. Larger-than-expected variability decreased the power of the study and increased the possibility of a type 2 statistical error. Conclusion: Astaxanthin (12 mg/d for 12 mo) had no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients. This trial was registered at the Australian New Zealand Clinical Trials Registry (http://www.anzctr. org.au/) as ACTRN12608000159358.
INTRODUCTION
Vascular disease is the leading cause of morbidity and mortality in renal transplant recipients (1) . Immunosuppressive therapy increases oxidative stress and inflammation, which results in vascular dysfunction (2) , and these processes are believed to be central in the pathogenesis of cardiovascular disease in these patients (3) . Measures of arterial stiffness such as aortic pulse wave velocity (PWV) 4 are a strong predictor of mortality in renal transplant recipients (4) .
Nutritional antioxidants have the ability to decrease lipid and protein oxidation, potentially protecting against atherosclerosis and arterial stiffness (5) . Although data from epidemiologic (6) (7) (8) , animal (9) , and in vitro (10) studies have supported the notion that increased antioxidant intake will decrease the risk of atherosclerosis and vascular disease, large randomized controlled trials have not supported this postulate (11, 12) . However, in patients with kidney disease antioxidant therapy has been more successful (13, 14) . Given the lack of available therapies to lower oxidative stress and inflammation and improve clinical outcomes, more research is required to evaluate novel therapies with different biological actions. This is especially important in high-risk groups such as renal transplant recipients.
Astaxanthin is a xanthophyll carotenoid, but compared with other carotenoids it contains 2 additional oxygenated groups on each ring structure, resulting in enhanced antioxidant properties (15, 16) . The compound occurs naturally in a wide variety of living organisms, including microalgae, fungi, complex plants, and crustaceans. It is reddish-colored and gives salmon, shrimp, and lobster their distinctive color. It quenches reactive oxygen 1 Cyanotech Corporation supported this study and provided the astaxanthin and identical placebo; however, they had no role in the study concept and design, data acquisition and analysis, drafting of the manuscript, or decision to pursue publication.
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and nitrogen species and 1-and 2-electron oxidants and is a chain breaker of free radicals (17) (18) (19) .
Astaxanthin has been shown to decrease biomarkers of oxidative stress, inflammation, or both in healthy men (20, 21) and women (22) , patients with functional dyspepsia (23), overweight and obese participants (24) , and smokers (25) . Another study reported astaxanthin improved whole-blood transit time (blood rheology) in healthy men (26) . However, these studies were small and generally of low methodologic quality (27) . Furthermore, astaxanthin has yet to be investigated in renal transplant recipients who have elevated oxidative stress and inflammation (28, 29) , and who may benefit more from having these variables normalized. Therefore, the aim of this study was to assess the effect of astaxanthin on arterial stiffness, oxidative stress, and inflammation in renal transplant recipients.
METHODS

Patient selection
The study protocol for XANTHIN has been published (30) . The study was a multicenter, double-blind (participants and study staff), randomized (1:1 allocation), parallel, placebo-controlled trial. It was designed to be conducted at the Launceston General Hospital and Burnie Satellite Renal Units in Northern Tasmania, Australia. However, less than anticipated accrual resulted in a third site at the Royal Brisbane and Women's Hospital, Australia. Ethics committees at each location approved the study [approval numbers: H0008414 (Tasmania, both sites), HREC/09/QRBW/32 (Queensland)]. This trial was registered at the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/) as ACTRN12608000159358. Inclusion criteria were as follows: age .18 and ,85 y and having undergone renal transplantation. Subjects were excluded if they were taking antioxidant supplementation, unable to take glyceryl trinitrate (GTN), or were participating in, or proposed to participate in, another clinical drug study within 30 d before study entry. Recruitment was performed by study nurses at each location. The trial commenced in 2007 and finished in 2013 after recruitment had significantly slowed.
Randomization
Sixty-one patients were randomly assigned to either the astaxanthin or identical placebo groups by using a computer random-assignment program. Clinical trial pharmacists at each location who were independent of the study team performed the randomization and allocation. Participants were stratified according to the type of immunosuppression used for the renal transplant: 1) cyclosporine, 2) tacrolimus, 3) sirolimus and 4) prednisolone together with azathioprine, mycophenolate mofetil, or mycophenolate sodium.
Study medication and dosing
Active treatment entailed 12 mg orally administered astaxanthin/d (BioAstin; Cyanotech Corporation). The astaxanthin was derived from Haematococcus pluvialis (microalgae). Each participant was required to take three 4-mg capsules (at 1 time point) of astaxanthin per day or a placebo for 12 mo. A small substudy was conducted to determine the effects of an acute dose of astaxanthin on oxidative stress. We previously used a maximal exercise test to induce oxidative stress and showed that this increases plasma F2-isprostanes postexercise by 27% (31) . Our substudy showed that an acute dose of 12 mg astaxanthin taken 1 h before a maximal exercise test significantly decreased F2-isprostanes in healthy men by 37% (200 6 32 to 125 6 15 ng/mL).
Primary outcomes
The primary outcome measures were arterial stiffness (PWV), oxidative stress (total F2-isoprostanes), and inflammation (pentraxin-3). There were no changes to trial outcomes after the trial commenced.
PWV
Carotid to femoral PWV was derived by electrocardiographygated sequential applanation tonometry (SPT-301 Mikro-Tip; Millar Instruments) by using the foot-to-foot method (SphymoCor 7.01; AtCor) (32) . Testing was performed in a temperaturecontrolled room and after 5-10 min rest with the subject in the supine position before the first measure. Two measures were averaged for the estimation of aortic PWV. The same technician performed all measures, and her reliability taken from 10 individuals measured at the same time of day on 2 separate days was 4.6%.
Total F2-isoprostanes
Total (esterified and nonesterified) F2-isoprostanes in plasma were measured by using gas chromatography-mass spectrometry with the use of a protocol developed in our laboratory (33) .
Pentraxin-3
An ELISA was used to measure plasma pentraxin-3 concentrations.
Secondary outcomes
Vascular function, carotid artery intima-media thickness (CIMT), augmentation index (AIx), central blood pressure (CBP), subendocardial viability ratio (SEVR), and additional measures of oxidative stress and inflammation were secondary outcomes.
Vascular function and CIMT
A 12-MHz linear array transducer and ultrasound scanner (Vivid i; GE Healthcare) was used to measure vascular function and CIMT. Vascular function was assessed as the change in diameter of the brachial artery during flow-mediated dilatation and due to the administration of sublingual GTN. These represent measures of endothelium-dependent (flow-mediated dilatation) and -independent (GTN) vascular function (34) . CIMT refers to the combined thickness of the intimal and medial layers of the carotid arterial wall. This corresponds to the inner and outer echogenic lines seen on the B-mode ultrasound image. Images were acquired from the anterior, posterior, and lateral planes of the right common carotid artery (35) . wave and is used as an additional marker of arterial stiffness. CBP reflects left ventricular afterload, and SEVR is an index of myocardial oxygen supply and demand.
Oxidative stress and inflammation
Additional measures of oxidative stress and antioxidant status were plasma protein carbonyls, total antioxidant capacity, glutathione peroxidase activity, and, for inflammation, C-reactive protein.
Additional measures
At the first trial visit, demographic and clinical data (height, weight, blood lipids, liver function, electrolytes, bicarbonate, calcium, parathyroid hormone urea) were collected. The blood data were obtained from a routine pathology visit. An accredited pathology laboratory associated with the patient's hospital performed all clinical biochemical measures. Plasma astaxanthin concentration was determined by using reverse-phase HPLC (Shimadzu VP series; Shimadzu) (36) . Adherence to study medication was assessed by capsule counting. Participants were provided with 300 capsules for 6 mo, which was more than required. They were then asked to return the capsule container at the 6-mo visit, and the difference between 300 and the number of capsules that should have been consumed (on the basis of number of days in the trial) was compared. Participants were then given another 6-mo supply of capsules.
Safety
On the basis of our previous finding that antioxidant supplementation with vitamin E resulted in a reduction in blood immunosuppressant concentrations (37), patients had a blood 1 Comparisons between groups were assessed by an independent t test on normally distributed and log-transformed variables. The Mann-Whitney U test was performed for non-normally distributed variables. Differences between groups for categorical variables were analyzed by using Pearson's chi-square test. ACE, angiotensin-converting enzyme; HMG-CoA, b-hydroxy-b-methylglutaryl coenzyme A. 2 Astaxanthin and placebo groups. 3 Mean 6 SD (all such values).
sample analyzed after 1 wk of astaxanthin or placebo therapy to measure immunosuppressant concentrations. These analyses were conducted at an accredited pathology laboratory associated with the patient's hospital. The nephrologist treating the patient interpreted this value on the basis of knowledge of the patient's medication and immunosuppressant-concentration history to make a clinical judgement with regard to the potential effects of astaxanthin. Additional safety data were obtained during the trial visits by using standard adverse event questions.
Statistical analysis
The sample size goal of 66 was based on a change in PWV of 1 m/s (SD = 1.1) over 12 mo to be clinically significant (power = 0.9, a = 0.05). Continuous data were checked for normality by using Kolmogorov-Smirnov and Shapiro-Wilk tests. Data with a normal distribution were log-transformed (natural log) and checked for normality. All tables indicate whether statistical analyses were performed with the use of log-transformed data or nonparametric tests (for log-transformed data that were not normally distributed). Original data with a normal distribution are shown as means 6 SDs, whereas medians and IQRs are provided for other continuous variables. Comparisons between groups for baseline variables were assessed by an independent t test on normally distributed and log-transformed variables.
The Mann-Whitney U test was performed for non-normally distributed variables. Differences between groups for categorical variables were analyzed by using Pearson's chi-square test. General linear mixed-effects modeling was used to compare the mean rate of change in primary outcome measures within and between groups, unadjusted and adjusted for actual and potential confounding variables. All analyses were performed by using SPSS 20.0 (IBM). Table 1 provides baseline demographic characteristics, medication usage, causes of kidney failure, and comorbidities. Randomization was effective because there were no significant differences between groups for any of these measures. Compliance, assessed by capsule counting, was very high at 92% for the 12 mo. Blood tests after 1 wk of taking the supplement showed no indication of an effect of the supplement on immunosuppressant concentrations. No adverse events were ascribed to the interventions during the trial. Figure 1 shows the patient flow. There was excellent patient retention, with 58 of the 61 randomly assigned patients (95%) returning for trial visits at 6 and 12 mo.
RESULTS
There were no significant differences within or between astaxanthin and placebo with regard to the 3 primary outcome measures (Tables 2 and 3) . Over 12 mo, PWV changed by +9.5% and +6.0%, F2-isoprostanes changed by 23.0% and 29.7%, and pentraxin-3 changed by +50.6% and 211.0% in the placebo and astaxanthin groups, respectively. Additional vascular structure and function measures are provided in Table 2 . There were no significant within-or between-group differences in any of the measures. There were also no significant within-or between-group differences in additional biochemical measures (Table 3) .
Patients were categorized according to their baseline inflammatory and oxidative stress measures. By using 1 SD above the mean as a group divider, there were no differences in the changes in oxidative stress measures between the astaxanthin and placebo group members who had elevated F2-isoprostanes or elevated pentraxin-3 at baseline (data not shown).
DISCUSSION
To our knowledge, this is the largest randomized placebocontrolled trial that used the antioxidant astaxanthin. We found that 1 y of 12 mg orally administered astaxanthin/d had no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients. There were no group differences in a range of secondary outcome measures, including vascular function, CIMT, and additional measures of oxidative stress and inflammation. The larger-than-expected variability in the change in the primary outcome measures reduced the statistical power and increased the chance of a type 2 error.
The rationale for conducting the study was based on the following: 1) evidence from .10 animal studies that showed that astaxanthin improved cardiovascular variables (38) , including vascular elastin and arterial wall thickness in hypertensive rats (39) ; 2) a demonstrated ability to decrease oxidative stress and inflammation in rodents (40) and from a range of small human trials (20) (21) (22) (23) (24) (25) ; and 3) evidence showing novel antioxidant abilities (15) . The failure of astaxanthin to have a clinical effect after showing promise in experimental and smaller studies is not unusual for an antioxidant. Indeed, animal studies have continually shown the benefits of vitamins E and C and b-carotene for numerous experimental biochemical, physiologic, and pathophysiologic processes in rodents (41) , but randomized controlled trials in humans that used these supplements have generally failed to find clinical benefits (11, 12) . It is important to realize that the antioxidant systems of humans and rodents are different: for example, humans are unable to synthesize vitamin C, whereas rodents can (42) . This has led to ongoing skepticism of the value of antioxidant rodent research for clinical translation (43) .
Additional possible explanations for the lack of an effect could be due to the dose or the length of the intervention. At the time this trial was designed, ,10 studies that used astaxanthin had been conducted in humans. Our dose of 12 mg/d was based on knowledge at the time that 6 mg/d was safe (44) and that a dose of 14.4 mg/d decreased LDL oxidation (21) . Indeed, our blood data indicate that the astaxanthin was absorbed, with plasma General linear mixed-effects modeling was used to compare the mean rate of change in primary outcome measures within and between groups, unadjusted and adjusted for actual and potential confounding variables. CIMT, carotid artery intima-media thickness; FMD, flow-mediated dilation; GTN, glyceryl trinitrate; PWV, pulse wave velocity; SEVR, subendocardial viability ratio. 14 mmol/L) in a study that found that the supplement decreased markers of oxidative stress and inflammation in humans (22) . Although it was suggested that antioxidant trials need to last at least 5 y to see a demonstrable benefit of the vasculature (45), other interventions, such as exercise training, reported significant changes in vascular function after w3 mo (46) . Supplementation with astaxanthin failed to affect markers of oxidative stress and inflammation at either 6 or 12 mo. A limitation is that we did not have evidence that the compound showed antioxidant or anti-inflammatory properties in renal transplant patients over this duration before commencing the study. Our rationale was based on these effects in other populations and over shorter time periods.
The study was powered to detect a 1-m/s change in PWV between groups over the 12 mo (power = 0.9, a = 0.05). However, the variability in the change in PWV was greater than expected (SD: 1.7 compared with 1.1 m/s). This increased the chance that our PWV finding represents a type 2 statistical error. To detect a 1-m/s difference over 12 mo between groups with the variability we found, and the same power and a level, would require 124 patients completing a 2-group randomized controlled trial. With regard to the clinical significance of this surrogate measure in kidney transplant recipients, each 1-m/s increase in PWV has been associated with an increased mortality HR of 1.36 (95% CI: 1.14, 1.62) (4) . The study protocol recognized that good statistical power for the F-2 isoprostanes and pentraxin-3 measures depended on low variability in the change scores, which we did not find.
In summary, 12 mg oral astaxanthin/d had no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients. We should not discount the possibility that the lowerthan-expected statistical power increased the chance that these are false-negative findings. The data will be useful for future studies and meta-analyses. The authors' responsibilities were as follows-all authors: designed and conducted the research, provided essential reagents or materials, analyzed the data, and wrote the manuscript; and JSC: had primary responsibility for the final content. All of the authors provided critical revision of the manuscript for important intellectual content and read and approved the final manuscript. RGF was a director of ASTASci Pty. Ltd. for 4 mo from December 2014 to March 2015. ASTASci was a company that imported and sold astaxanthin-containing products into Australia. Neither of the other 2 authors reported a conflict of interest related to the study. General linear mixed-effects modeling was used to compare the mean rate of change in primary outcome measures within and between groups, unadjusted and adjusted for actual and potential confounding variables. AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; K + , potassium; Na + , sodium; ND, not detected; g-GT, g-glutamyltransferase. 
